Literature DB >> 6625007

The dexamethasone suppression test in psychotic disorders.

G W Arana, P J Barreira, B M Cohen, J F Lipinski, D Fogelson.   

Abstract

Dexamethasone suppression tests were given to 69 consecutively admitted psychiatric patients. Nonsuppression rates for depression with or without melancholia and for schizophrenia were similar to those previously reported, but for mania and other psychoses the frequencies were higher than expected.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6625007     DOI: 10.1176/ajp.140.11.1521

Source DB:  PubMed          Journal:  Am J Psychiatry        ISSN: 0002-953X            Impact factor:   18.112


  5 in total

1.  Glucocorticoid receptor dysfunction: consequences for the pathophysiology and treatment of mood disorders.

Authors:  Aju Abraham; Stuart Watson; Allan H Young
Journal:  Indian J Psychiatry       Date:  2003-04       Impact factor: 1.759

2.  Anti-purkinje cell and natural autoantibodies in a group of psychiatric patients. Evidences for a correlation with the psychopathological status.

Authors:  Roberto Delle Chiaie; Brunella Caronti; Francesco Macrì; Sandra Campi; Marzia Marino; Alessandra Corrado; Maria Caredda; Massimo Biondi
Journal:  Clin Pract Epidemiol Ment Health       Date:  2012-08-23

Review 3.  A new nosology of psychosis and the pharmacological basis of affective and negative symptom dimensions in schizophrenia.

Authors:  Costa Vakalopoulos
Journal:  Ment Illn       Date:  2010-05-06

4.  Corticosterone oscillations during mania induction in the lateral hypothalamic kindled rat-Experimental observations and mathematical modeling.

Authors:  Osama A Abulseoud; Man Choi Ho; Doo-Sup Choi; Ana Stanojević; Željko Čupić; Ljiljana Kolar-Anić; Vladana Vukojević
Journal:  PLoS One       Date:  2017-05-18       Impact factor: 3.240

5.  HPA axis genetic variation, cortisol and psychosis in major depression.

Authors:  A F Schatzberg; J Keller; L Tennakoon; A Lembke; G Williams; F B Kraemer; J E Sarginson; L C Lazzeroni; G M Murphy
Journal:  Mol Psychiatry       Date:  2013-10-29       Impact factor: 15.992

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.